Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

82.93 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Mirum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

November 09, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Presents New Data from LIVMARLI Phase 3 PFIC Study and ALGS Infant Study in Late-Breaker Presentations at The Liver Meeting of AASLD

November 07, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022

November 01, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum’s LIVMARLI Data Featured in Two Late-Breaker Presentations at The Liver Meeting of the American Association for the Study of Liver Diseases

October 31, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Recap: Mirum Pharmaceuticals Q2 Earnings ↗

August 04, 2022

Mirum Pharmaceuticals (NASDAQ:MIRM) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Why Taysha Gene Therapies Shares Jumped Over 97%; Here Are 70 Biggest Movers From Yesterday ↗

October 26, 2022

Gainers Taysha Gene Therapies, Inc. (NASDAQ: TSHA) surged 97.4% to close at $2.98 after Astellas Pharma Inc announced it will invest a total of $50 million to acquire 15% of the company.

Via Benzinga

Analysts Expect Mirum Pharma's Liver Disease Candidate Might Exceed Rival Product's Penetration ↗

October 25, 2022

Via Benzinga

Positive Topline Data Announced from Mirum’s LIVMARLI Phase 3 MARCH Study in Progressive Familial Intrahepatic Cholestasis (PFIC)

October 24, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals’ LIVMARLI Data Highlighting Quality of Life and Sleep Improvements in Patients with Alagille Syndrome Published in Journal of Pediatrics

October 18, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for Cholestatic Pruritus in Patients with Alagille Syndrome Two Months of Age and Older

October 14, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Presents Long-Term LIVMARLI® (maralixibat) Data and New Alagille Syndrome Caregiver Burden Analysis at NASPGHAN 2022 Annual Meeting

October 12, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 10, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Present LIVMARLI® (maralixibat) Analyses and Host a Scientific Symposium at NASPGHAN 2022 Annual Meeting

October 05, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 12, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022 ↗

September 01, 2022

Upgrades

Via Benzinga

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

August 30, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

'It Is Too Sizzling For Me': Why Jim Cramer Isn't Buying This 'Red Hot' Group Of Stocks ↗

August 30, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Kelly Services, Inc. (NASDAQ: KELYA) is a "very well-run company. Right now, with people just feeling it’s easy to get a job, you don’t need them....

Via Benzinga

Looking Into Mirum Pharmaceuticals's Return On Capital Employed ↗

August 23, 2022

According to Benzinga Pro data, during Q2, Mirum Pharmaceuticals (NASDAQ:MIRM) posted sales of $17.48 million. Earnings were up 26.45%, but Mirum Pharmaceuticals still reported an overall loss of...

Via Benzinga

Mirum Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock

August 12, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 10, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Here's Why Mirum Pharmaceuticals Stock Is Getting Hammered ↗

August 10, 2022

Mirum Pharmaceuticals Inc (NASDAQ: MIRM) shares are trading lower by 13.46% to $23.79 Wednesday afternoon after the company priced its common stock offering of 3.478 million shares at $23 per share....

Via Benzinga

Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial ↗

August 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Mirum Pharmaceuticals Announces Pricing of Public Offering of Common Stock

August 09, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Announces Commencement of Public Offering of Common Stock

August 09, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

August 04, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022

July 28, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 08, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Highlights Data Demonstrating Impact of LIVMARLI® (maralixibat) on Patients with Alagille Syndrome at European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting

June 24, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Presents New Data at The International Liver Congress™ of the European Association for the Study of the Liver (EASL)

June 24, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Showcase LIVMARLI® (maralixibat) Data at EASL and ESPGHAN Annual Congresses

June 13, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.